Answers are grounded in this paper and cite their sources.
Due to recent advances in disease proteomics, many disease-related proteins have been found. It is expected that there will be therapeutically useful proteins among them. However, it is clinically difficult to use most proteins as effective and safe drugs because of their very low stability and pleiotropic actions in vivo. To promote disease proteomic based drug development for protein therapies, we have attempted to develop an optimal polymer-conjugation system for improving the therapeutic potency of proteins. In this review, we introduce this innovative protein-drug system.
No takes yet. Share an insight, caveat, or question.
Shibata et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: